Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TACR2 | P21452 | 2/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234409 | 0.91 | TACR3 (0.84) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4237366 | 0.90 | TACR3 (1.00) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4239466 | 0.90 | TACR3 (0.86) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4237097 | 0.90 | TACR3 (1.00) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4239201 | 0.89 | TACR3 (0.83) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4243559 | 0.89 | TACR3 (0.80) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4237701 | 0.89 | TACR3 (0.84) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4234347 | 0.89 | TACR3 (1.00) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4234685 | 0.89 | TACR3 (0.84) | TACR3KCNH2CYP3A4TACR2 | |
| SCHEMBL4241684 | 0.89 | TACR3 (0.84) | TACR3KCNH2CYP3A4TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | claimed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| EP-1888530-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120478-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | TACR3 2/4885KCNH2 41/4885CYP3A4 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.